Market Overview

Regenacy Pharmaceuticals Announces Patent Issuance for Ricolinostat to Treat Diabetic Peripheral Neuropathy

Share:

Regenacy
Pharmaceuticals, LLC
, a clinical-stage biopharmaceutical company
developing breakthrough treatments for diabetic and other peripheral
neuropathies, today announced the issuance of U.S. Patent No. 10,040,769
covering the use of ricolinostat (ACY-1215) for the treatment of
diabetic peripheral neuropathy (DPN). Ricolinostat is an oral, selective
inhibitor of the microtubule modifying enzyme HDAC6 with first-in-class
potential. The patent covering this new method of treatment was issued
on August 7, 2018.

"This patent issued by the U.S. Patent and Trademark Office expands our
intellectual property protection for this exciting drug candidate, which
has the potential to address a major unmet need for many millions of
diabetic patients," said Simon Jones, Ph.D., Regenacy's President and
Chief Executive Officer.

Ricolinostat is protected by issued U.S. and foreign composition of
matter patents with additional method-of-use patents positioned to issue
for diabetic, chemotherapeutic and inherited neuropathies, as well as
polycystic kidney disease. Based on previously completed studies,
ricolinostat has been proven to reverse neuropathic pain and correct
metabolic defects in rat models of diabetic neuropathy, and restore
impaired mitochondrial transport in neurons cultured in high glucose.
These pre-clinical findings suggest ricolinostat has the potential to be
a unique, first-in-class, disease modifying treatment with the potential
to restore peripheral nerve function.

"Temporary, symptomatic treatments for neuropathic pain associated with
DPN are poorly tolerated, minimally effective and some can be addictive.
Ricolinostat aims to provide lasting relief of all symptoms, has the
potential to reverse neuropathic pain and, unlike standard analgesics,
may restore peripheral nerve function to reverse the loss of feeling in
the feet and hands," said Matt Jarpe, Ph.D., Vice President of R&D of
Regenacy Pharmaceuticals.

About Regenacy
Regenacy Pharmaceuticals, LLC is a
clinical-stage biopharmaceutical company regenerating biological
function by protein acetylation for the treatment of diabetic and other
peripheral neuropathies and other chronic conditions. The company's
selective inhibition technology provides superior safety profiles and
potential enhanced efficacy compared to non-selective HDAC inhibitors.
Regenacy selectively inhibits histone deacetylase 6 (HDAC6) to restore
normal intracellular protein and organelle transport in peripheral
neuropathies, and also has a portfolio of selective HDACs 1 and 2
inhibitors that have potential to treat major blood diseases such as
sickle cell disease, β-thalassemia, leukemia, and cognitive dysfunction
in neurological disorders. www.regenacy.com

View Comments and Join the Discussion!